AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV - Changing to HIV.gov in Spring 2017

MENU

Clinical Trials

NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection….

New study underscores the power of HIV testing and treatment

It’s been four years since a clinical trial showed that early treatment of HIV infection can dramatically reduce the chances of HIV transmission. In that time, our nation’s prevention efforts have been transformed to help get many more people with HIV diagnosed and into care, both for their own health and to reduce HIV infections…

NIH Launches ClinRegs Website on International Clinical Research Regulations

An online database of country-specific clinical research regulatory information is now available at clinregs.niaid.nih.gov. Developed by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), the ClinRegs website is designed to help the research community plan international clinical trials more efficiently by consolidating regulatory requirements in one place and enabling comparisons across countries. By providing…

Researchers Find Hepatitis C Cures Effective for People Living with HIV/HCV Coinfection – Reports from AIDS 2014

The World Health Organization estimates that globally, 5-15% of people living with HIV are coinfected with hepatitis C. In the United States, about 25% of people living with HIV also have hepatitis C (HCV)—and HCV rates are even higher among people with HIV who inject drugs. For both hepatitis B and hepatitis C infection, disease…

HIV Vaccine Awareness Day

Watch NIAID Director Anthony S. Fauci, M.D., discuss current HIV vaccine research approaches. Developing a safe and sufficiently effective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic. The path to an HIV vaccine has not been—and will not be—an easy one. In the 27…

NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks

The National Institute of Allergy and Infectious Diseases (NIAID) has selected the principal investigators and clinical trials units (CTUs) that will lead and conduct the research of the five restructured HIV/AIDS clinical trials networks through 2021. The new structure is designed to create a broader, more flexible and more collaborative approach to the networks’ research priorities, which…

NIH Statement on World AIDS Day 2013

In the 25 years that have passed since the first annual commemoration of World AIDS Day, extraordinary scientific progress has been made in the fight against HIV/AIDS. That progress has turned an HIV diagnosis from an almost-certain death sentence to what is now for many, a manageable medical condition and nearly normal lifespan. We have…

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…